Geode Capital Management’s aTyr Pharma ATYR Stock Holding History

Geode Capital Management’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$703K	Sell	1,177,020 -1,208,465	-51%	-$789K	﹤0.01%	3475
2026 Q1	$1.86M	Buy	2,385,485 +101,768	+4%	+$85.9K	﹤0.01%	3152
2025 Q4	$1.79M	Buy	2,283,717 +105,514	+5%	+$86.6K	﹤0.01%	3207
2025 Q3	$1.57M	Buy	2,178,203 +80,127	+4%	+$363K	﹤0.01%	3263
2025 Q2	$10.6M	Buy	2,098,076 +1,170,276	+126%	+$4.6M	﹤0.01%	2329
2025 Q1	$2.8M	Buy	927,800 +36,393	+4%	+$133K	﹤0.01%	2922
2024 Q4	$3.23M	Buy	891,407 +82,306	+10%	+$249K	﹤0.01%	2951
2024 Q3	$1.42M	Buy	809,101 +146,417	+22%	+$266K	﹤0.01%	3236
2024 Q2	$1.03M	Buy	662,684 +67,573	+11%	+$118K	﹤0.01%	3292
2024 Q1	$1.16M	Buy	595,111 +8,114	+1%	+$14.2K	﹤0.01%	3314
2023 Q4	$828K	Hold	586,997	–	–	﹤0.01%	3422
2023 Q3	$928K	Sell	586,997 -6,477	-1%	-$12K	﹤0.01%	3354
2023 Q2	$1.28M	Buy	593,474 +14,572	+3%	+$31.8K	﹤0.01%	3255
2023 Q1	$1.22M	Buy	578,902 +336,663	+139%	+$738K	﹤0.01%	3254
2022 Q4	$530K	Buy	242,239 +2,743	+1%	+$6.47K	﹤0.01%	3638
2022 Q3	$718K	Buy	239,496 +687	+0.3%	+$2.3K	﹤0.01%	3551
2022 Q2	$675K	Buy	238,809 +4,487	+2%	+$16.2K	﹤0.01%	3596
2022 Q1	$1.25M	Buy	234,322 +2,823	+1%	+$16K	﹤0.01%	3508
2021 Q4	$1.73M	Buy	231,499 +101,217	+78%	+$845K	﹤0.01%	3444
2021 Q3	$1.18M	Buy	130,282 +20,521	+19%	+$123K	﹤0.01%	3598
2021 Q2	$535K	Buy	109,761 +49,513	+82%	+$211K	﹤0.01%	3913
2021 Q1	$268K	Buy	60,248 +11,650	+24%	+$54.8K	﹤0.01%	4025
2020 Q4	$188K	Buy	48,598 +2,468	+5%	+$9.02K	﹤0.01%	3905
2020 Q3	$148K	Hold	46,130	–	–	﹤0.01%	3809
2020 Q2	$204K	Buy	46,130 +33,090	+254%	+$120K	﹤0.01%	3656
2020 Q1	$36K	Hold	13,040	–	–	﹤0.01%	3972
2019 Q4	$54K	Hold	13,040	–	–	﹤0.01%	4076
2019 Q3	$45K	Buy	+13,040	New	+$48K	﹤0.01%	4077
2019 Q2	–	Sell	-7,572	Closed	-$58K	–	4243
2019 Q1	$58K	Hold	7,572	–	–	﹤0.01%	3995
2018 Q4	$52K	Hold	7,572	–	–	﹤0.01%	3985
2018 Q3	$86K	Hold	7,572	–	–	﹤0.01%	3962
2018 Q2	$96K	Hold	7,572	–	–	﹤0.01%	3874
2018 Q1	$280K	Hold	7,572	–	–	﹤0.01%	3593
2017 Q4	$371K	Sell	7,572 -207	-3%	-$12.7K	﹤0.01%	3468
2017 Q3	$549K	Hold	7,779	–	–	﹤0.01%	3327
2017 Q2	$375K	Sell	7,779 -234	-3%	-$11K	﹤0.01%	3452
2017 Q1	$392K	Buy	8,013 +32	+0.4%	+$1.46K	﹤0.01%	3400
2016 Q4	$240K	Buy	7,981 +21	+0.3%	+$861	﹤0.01%	3554
2016 Q3	$354K	Buy	7,960 +4,966	+166%	+$215K	﹤0.01%	3386
2016 Q2	$116K	Sell	2,994 -359	-11%	-$16.7K	﹤0.01%	3760
2016 Q1	$184K	Sell	3,353 -5	-0.1%	-$380	﹤0.01%	3660
2015 Q4	$462K	Buy	3,358 +224	+7%	+$31.9K	﹤0.01%	3306
2015 Q3	$450K	Buy	+3,134	New	+$714K	﹤0.01%	3266

Other funds holding ATYR

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $174M AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management's ATYR Position: Q2 2026 in Review

Geode Capital Management reduced its aTyr Pharma (ATYR) stake by 51% in Q2 2026, selling an estimated $789K and leaving 1,177,020 shares worth $703K. The position accounts for ﹤0.01% of the portfolio, ranked #3475.

Geode Capital Management first reported a position in ATYR in Q3 2015 and has held it in 43 quarters since. The position peaked at $10.6M in Q2 2025. 90 funds tracked by Wall St. Rank hold ATYR as of Q2 2026.

Geode Capital Management held 1,177,020 shares of aTyr Pharma worth $703K as of Q2 2026.
Geode Capital Management sold 1,208,465 aTyr Pharma shares in Q2 2026, an estimated $789K.
aTyr Pharma made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #3475 holding.
Geode Capital Management first reported a position in aTyr Pharma in Q3 2015 and has held it in 43 quarters since.
Geode Capital Management's aTyr Pharma position peaked at $10.6M in Q2 2025.
90 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.